April 13, 2010 - Full-Service Options Help Move Treatments Through Proof-of-Concept More Quickly – Cetero Research, the leading early-stage contract research organization (CRO), announced it has completed more than 500 diabetes research studies in the past three years for both Type 1 and Type 2 diabetics, including complex clamp studies and studies in Phase I, II, III and IV. Cetero is the only CRO that can combine both pivotal pharmacokinetic studies and proof-of-concept studies in one study, saving up to six months of development time.“Approximately eight percent of the U.S. population struggles with diabetes, and the numbers continue to grow. Our ability to provide researchers with the support they need to expedite new drug development is extremely important,”... Cetero Research's Press Release -
